Stealth BioTherapeutics Corp Stock News

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of Stealth

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial d

Stealth BioTherapeutics Corp (NASDAQ:MITO) has earned a consensus recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rate

Stealth BioTherapeutics Corp (NASDAQ:MITO) was up 13% on Thursday . The company traded as high as $1.74 and last traded at $1.56, approximately 316,522 shares were traded during mid-day trading. A dec

As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

Stealth BioTherapeutics (NASDAQ:MITO) had its price target cut by Nomura from $14.00 to $10.00 in a research report report published on Friday, The Fly reports. They currently have a buy rating on the

Stealth BioTherapeutics Corp (NASDAQ:MITO) – Research analysts at Jefferies Financial Group issued their Q3 2020 EPS estimates for Stealth BioTherapeutics in a research note issued to investors on T

Stealth BioTherapeutics Corp (NASDAQ:MITO) – Stock analysts at Jefferies Financial Group issued their Q1 2020 EPS estimates for shares of Stealth BioTherapeutics in a report issued on Thursday, Apri

Stealth BioTherapeutics (NASDAQ:MITO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday, Zacks.com reports. The brokerage pre